secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276062
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC
----------------------------------------------------------------------------

- Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.
- Cash, equivalents $104M at Sep 30; raised $73.8M net in Oct-Nov offering extending runway into 2028.
- CRB-701 ESMO data: ORR 47.6% (HNSCC), 37.5% (cervical), 55.6% (mUC) at 3.6 mg/kg; registrational study planned mid-2026.
- CRB-913 SAD/MAD study on track; Ph1b in obese patients to start Q4 2025.
- CRB-601 Phase 1 dose escalation ongoing; first participant dosed Dec 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/0001193125-25-276062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/crbp-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer